Oncocyte Corp Enters Material Definitive Agreement
Ticker: IMDX · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1642380
| Field | Detail |
|---|---|
| Company | Oncocyte Corp (IMDX) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1,700,000, $60,714.29 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Oncocyte Corp signed a big deal on Jan 2, 2025. Details TBD.
AI Summary
On January 2, 2025, Oncocyte Corporation entered into a material definitive agreement. The filing does not provide specific details about the agreement or any associated dollar amounts. The company is incorporated in California and its principal executive offices are located in Irvine, California.
Why It Matters
This filing indicates a significant new contract or partnership for Oncocyte Corporation, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its terms and potential impact.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- January 2, 2025 (date) — Date of earliest event reported
- California (location) — State of incorporation
- Irvine, California (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Oncocyte Corporation?
The filing states that Oncocyte Corporation entered into a material definitive agreement on January 2, 2025, but does not provide specific details about its nature.
Are there any financial terms or dollar amounts associated with this agreement?
The provided filing does not specify any dollar amounts or financial terms related to the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 2, 2025.
Where are Oncocyte Corporation's principal executive offices located?
Oncocyte Corporation's principal executive offices are located at 15 Cushing, Irvine, California 92618.
What is Oncocyte Corporation's state of incorporation?
Oncocyte Corporation is incorporated in California.
Filing Stats: 816 words · 3 min read · ~3 pages · Grade level 15 · Accepted 2025-01-08 16:05:23
Key Financial Figures
- $1,700,000 — , the letter of credit in the amount of $1,700,000 (the "Letter of Credit Amount") that th
- $60,714.29 — shall be reduced by an amount equal to $60,714.29 on each such date, until the Letter of
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex10-1.htm (EX-10.1) — 29KB
- 0001493152-25-001389.txt ( ) — 242KB
- ocx-20250102.xsd (EX-101.SCH) — 3KB
- ocx-20250102_lab.xml (EX-101.LAB) — 33KB
- ocx-20250102_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: January 8, 2025 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer